A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection
- PMID: 23446627
- PMCID: PMC3641868
- DOI: 10.1093/cid/cit123
A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection
Abstract
Background: Staphylococcus aureus is among the leading causes of human infection. Widespread drug resistance, emergence of highly virulent strains, and the ability of S. aureus to colonize >30% of the human population contribute to this organism's pathogenic success. Human serologic responses to S. aureus and their relationship to protective immunity remain incompletely defined, challenging the strategic development of efficacious vaccines.
Methods: We measured humoral responses to 2 staphylococcal exotoxins, α-hemolysin (Hla) and Panton-Valentine leukocidin (PVL; LukF-PV/LukS-PV subunits), both premier targets of current vaccine and immunotherapy development. We correlated acute and convalescent serum antibody levels with incidence of recurrent infection over 12 months follow-up in 235 children with S. aureus colonization, primary or recurrent skin and soft tissue infection, or invasive disease.
Results: Cutaneous infection elicited transient increases in anti-Hla and anti-PVL antibodies; however, subsequent infection risk was similar between primary and recurrent cutaneous infection cohorts. Patients with invasive infections had the lowest preexisting titers against Hla and LukF but displayed the highest convalescent titers. Across cohorts, convalescent anti-Hla titers correlated with protection against subsequent S. aureus infection.
Conclusions: Cutaneous S. aureus infection does not reliably provoke durable, protective immune responses. This study provides the first link between protection from disease recurrence and the humoral response to Hla, a virulence factor already implicated in disease pathogenesis. These observations can be utilized to refine ongoing vaccine and immunotherapy efforts and inform the design of clinical trials.
Keywords: Panton–Valentine leukocidin; Staphylococcus aureus; humoral immunity; α-hemolysin.
Comment in
-
Will there ever be a universal Staphylococcus aureus vaccine?Hum Vaccin Immunother. 2013 Sep;9(9):1865-76. doi: 10.4161/hv.25182. Epub 2013 Jun 21. Hum Vaccin Immunother. 2013. PMID: 23793522 Free PMC article. Review.
Similar articles
-
High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection.Clin Infect Dis. 2010 Nov 15;51(10):1138-46. doi: 10.1086/656742. Epub 2010 Oct 14. Clin Infect Dis. 2010. PMID: 20946065 Free PMC article.
-
Antibodies to S. aureus LukS-PV Attenuated Subunit Vaccine Neutralize a Broad Spectrum of Canonical and Non-Canonical Bicomponent Leukotoxin Pairs.PLoS One. 2015 Sep 14;10(9):e0137874. doi: 10.1371/journal.pone.0137874. eCollection 2015. PLoS One. 2015. PMID: 26367030 Free PMC article.
-
Pediatric antibody response to community-acquired Staphylococcus aureus infection is directed to Panton-Valentine leukocidin.Clin Vaccine Immunol. 2009 Jan;16(1):139-41. doi: 10.1128/CVI.00360-08. Epub 2008 Nov 12. Clin Vaccine Immunol. 2009. PMID: 19005019 Free PMC article.
-
Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes.Biosci Biotechnol Biochem. 2004 May;68(5):981-1003. doi: 10.1271/bbb.68.981. Biosci Biotechnol Biochem. 2004. PMID: 15170101 Review.
-
Will there ever be a universal Staphylococcus aureus vaccine?Hum Vaccin Immunother. 2013 Sep;9(9):1865-76. doi: 10.4161/hv.25182. Epub 2013 Jun 21. Hum Vaccin Immunother. 2013. PMID: 23793522 Free PMC article. Review.
Cited by
-
Enhanced Staphylococcus aureus protection by uncoupling of the α-toxin-ADAM10 interaction during murine neonatal vaccination.Nat Commun. 2024 Oct 8;15(1):8702. doi: 10.1038/s41467-024-52714-7. Nat Commun. 2024. PMID: 39379345 Free PMC article.
-
The Complex Intracellular Lifecycle of Staphylococcus aureus Contributes to Reduced Antibiotic Efficacy and Persistent Bacteremia.Int J Mol Sci. 2024 Jun 12;25(12):6486. doi: 10.3390/ijms25126486. Int J Mol Sci. 2024. PMID: 38928191 Free PMC article. Review.
-
Trained immunity in recurrent Staphylococcus aureus infection promotes bacterial persistence.PLoS Pathog. 2024 Jan 19;20(1):e1011918. doi: 10.1371/journal.ppat.1011918. eCollection 2024 Jan. PLoS Pathog. 2024. PMID: 38241414 Free PMC article.
-
Toxin-neutralizing Abs are associated with improved T cell function following recovery from Staphylococcus aureus infection.JCI Insight. 2024 Jan 18;9(4):e173526. doi: 10.1172/jci.insight.173526. JCI Insight. 2024. PMID: 38236641 Free PMC article.
-
The characteristics of pre-existing humoral imprint determine efficacy of S. aureus vaccines and support alternative vaccine approaches.Cell Rep Med. 2024 Jan 16;5(1):101360. doi: 10.1016/j.xcrm.2023.101360. Cell Rep Med. 2024. PMID: 38232694 Free PMC article.
References
-
- Hussain FM, Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus colonization in healthy children attending an outpatient pediatric clinic. Pediatr Infect Dis J. 2001;20:763–7. - PubMed
-
- Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis. 2003;37:1050–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HS021736/HS/AHRQ HHS/United States
- R01 AI097434/AI/NIAID NIH HHS/United States
- RC2-HG005680/HG/NHGRI NIH HHS/United States
- R01-AI097434/AI/NIAID NIH HHS/United States
- KL2-RR024994/RR/NCRR NIH HHS/United States
- K23 AI091690/AI/NIAID NIH HHS/United States
- KL2 RR024994/RR/NCRR NIH HHS/United States
- U54 AI057153/AI/NIAID NIH HHS/United States
- UL1-RR024999/RR/NCRR NIH HHS/United States
- R01-HS021736/HS/AHRQ HHS/United States
- K23-AI091690/AI/NIAID NIH HHS/United States
- UL1 RR024999/RR/NCRR NIH HHS/United States
- UL1-TR000448/TR/NCATS NIH HHS/United States
- UL1 RR024992/RR/NCRR NIH HHS/United States
- U54-AI057153/AI/NIAID NIH HHS/United States
- RC2 HG005680/HG/NHGRI NIH HHS/United States
- UL1-RR024992/RR/NCRR NIH HHS/United States
- UL1 TR000448/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
